Scarica l'app Stockscreener
5.61
1.41%
-0.08
Dopo l'orario di chiusura:
5.82
0.21
+3.74%
Precedente Chiudi:
$5.69
Aprire:
$5.7
Volume 24 ore:
930.20K
Relative Volume:
1.21
Capitalizzazione di mercato:
$300.62M
Reddito:
-
Utile/perdita netta:
$-42.05M
Rapporto P/E:
-1.9894
EPS:
-2.82
Flusso di cassa netto:
$-35.26M
1 W Prestazione:
+5.25%
1M Prestazione:
-1.92%
6M Prestazione:
+85.15%
1 anno Prestazione:
-5.08%
Intervallo 1D:
$5.60
$5.84
Intervallo di 1 settimana:
$5.03
$5.87
Portata 52W:
$2.77
$7.82
Protara Therapeutics Inc Stock (TARA) Company Profile
Nome
Protara Therapeutics Inc
Settore
Industria
Telefono
646-844-0337
Indirizzo
345 PARK AVENUE SOUTH, NEW YORK, NY
Confronta TARA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TARA
Protara Therapeutics Inc
|
5.61 | 304.91M | 0 | -42.05M | -35.26M | -2.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Protara Therapeutics Inc Stock (TARA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-16 | Iniziato | Scotiabank | Sector Outperform |
| 2025-03-14 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-10 | Ripresa | Guggenheim | Buy |
| 2021-06-04 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-17 | Iniziato | Oppenheimer | Outperform |
| 2020-10-19 | Iniziato | Cowen | Outperform |
| 2020-07-29 | Iniziato | Guggenheim | Buy |
Mostra tutto
Protara Therapeutics Inc Borsa (TARA) Ultime notizie
Protara Therapeutics completes $75 million stock offering - MSN
Can Protara Therapeutics Inc. stock attract ESG capital inflowsJuly 2025 Spike Watch & Free Weekly Chart Analysis and Trade Guides - ulpravda.ru
Why Protara Therapeutics Inc. stock could see breakout soonPortfolio Profit Report & AI Enhanced Trading Signals - ulpravda.ru
Why Protara Therapeutics Inc. stock is recommended by analystsMarket Activity Summary & Fast Gaining Stock Strategy Reports - ulpravda.ru
Should I hold or sell Protara Therapeutics Inc. stock in 2025Analyst Downgrade & Risk Adjusted Buy and Sell Alerts - ulpravda.ru
Why Protara Therapeutics Inc. stock is popular among millennialsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - ulpravda.ru
Is Protara Therapeutics Inc. stock in correction or buying zoneJuly 2025 PreEarnings & AI Forecast Swing Trade Picks - ulpravda.ru
How strong is Protara Therapeutics Inc. stock revenue growthRate Hike & Momentum Based Trading Ideas - ulpravda.ru
Protara begins patient dosing in phase 3 trial for IV choline therapy - Investing.com Nigeria
Protara Therapeutics (TARA) Begins Phase 3 THRIVE-3 Trial for Ke - GuruFocus
TARA Stock Initiated with 'Overweight' Rating by Piper Sandler | - GuruFocus
Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support - The Manila Times
Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Why analysts recommend Protara Therapeutics Inc. (1KPA) stock2026 world cup usa national team semifinals young talents counter attacking expert forecast statistical analysis - ulpravda.ru
Why Protara Therapeutics Inc. stock could outperform in 20252026 world cup usa national team quarterfinals young talents high defensive line tactical prediction insights - ulpravda.ru
Protara, Ceribell rise on FDA breakthrough designations - MSN
FDA grants breakthrough therapy designation to Protara’s LM treatment By Investing.com - Investing.com Nigeria
Protara Therapeutics slumps 12%, raises $75M equity at $5.75 per share - MSN
Movement Recap: How strong is Protara Therapeutics Inc stock revenue growthJuly 2025 PostEarnings & Long-Term Capital Growth Strategies - moha.gov.vn
Protara Therapeutics updates on TARA-002 development - The Pharma Letter
Protara, CeriBell rise on FDA breakthrough designations (TARA:NASDAQ) - Seeking Alpha
Protara Therapeutics (TARA) Gains FDA Designations for TARA-002 - GuruFocus
FDA grants breakthrough therapy designation to Protara’s LM treatment - Investing.com
Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations - The Manila Times
Protara Therapeutics Receives Both FDA Breakthrough Therapy - GlobeNewswire
Protara Therapeutics’ TARA-002 Study: A Potential Game-Changer for Lymphatic Malformations - MSN
Levels Update: How forex fluctuations impact Protara Therapeutics Inc 1KPA stock2025 Historical Comparison & Fast Entry and Exit Trade Plans - moha.gov.vn
Assenagon Asset Management S.A. Invests $1.34 Million in Protara Therapeutics, Inc. $TARA - Defense World
Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Naïve NMIBC Patients on Wednesday, December 3, 2025 - Sahm
Sentiment Watch: Can Protara Therapeutics Inc stock attract ESG capital inflows2025 EndofYear Setup & Weekly High Potential Stock Alerts - moha.gov.vn
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Protara Therapeutics, Inc. (NASDAQ:TARA) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Resistance Check: Is Protara Therapeutics Inc. (1KPA) stock attractive for dividend growth2025 Technical Patterns & Fast Entry Momentum Trade Alerts - moha.gov.vn
Protara Therapeutics raises $86.3 million in offering - MSN
Protara Therapeutics Raises $86.3 Million in Offering - TipRanks
Protara Therapeutics, Inc. (NASDAQ: TARA) details $86.3M equity raise from stock sale - Stock Titan
What analysts say about Protara Therapeutics Inc stockSwing Trading Ideas & Get Alerts Before Market Turns Ugly - earlytimes.in
Acorn Capital Advisors LLC Acquires 472,315 Shares of Protara Therapeutics, Inc. $TARA - MarketBeat
Protara Therapeutics, Inc. $TARA is Velan Capital Investment Management LP's 4th Largest Position - MarketBeat
Protara Announces Closing of $75 Million Public Offering - The Manila Times
Protara announces proposed public offering - MSN
Protara Therapeutics Completes $75 Million Stock Offering - TipRanks
Protara therapeutics raises $75 million in public offering - Investing.com
Protara Therapeutics Closes $75 Million Public Offering - marketscreener.com
Protara therapeutics raises $75 million in public offering By Investing.com - Investing.com India
Protara Therapeutics (Nasdaq: TARA) closes $75M stock sale of 13.0M shares at $5.75 - Stock Titan
HC Wainwright & Co. reiterates Protara Therapeutics (TARA) buy recommendation - MSN
Is Protara Therapeutics Inc a good long term investmentOptions Trading Strategies & High Return Trading Strategies - earlytimes.in
Protara Therapeutics Inc Azioni (TARA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.80%
4.56%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):